Latest Ratios: P/E Ratio 19.0x · EV/EBITDA 64.6x · ROE N/A. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $16.8B | $12.9B | $8.0B | $7.1B | $6.8B | $7.4B | $8.4B | $6.5B | $2.6B | $1.3B | $538M |
| Enterprise Value | $17.1B | $13.2B | $8.3B | $7.4B | $7.0B | $7.1B | $7.9B | $5.9B | $2.3B | $1.2B | $357M |
| P/E Ratio → | 19.01 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 12.66 | 18.68 | 21.92 | 26.58 | 133.82 | 947.34 | 1214.13 | 483.74 | 243.27 | 880.44 | 116.73 |
| P/B Ratio | — | — | — | — | 26.00 | 8.34 | 10.07 | 10.84 | 9.19 | 7.20 | 3.04 |
| P/FCF | 29.60 | 296.28 | — | — | — | — | — | — | — | — | — |
| P/OCF | 295.54 | 249.64 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 19.05 | 22.73 | 27.90 | 137.20 | 916.96 | 1143.29 | 441.76 | 217.00 | 752.76 | 77.58 |
| EV / EBITDA | 64.65 | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 302.15 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.1% | 85.1% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -18.9% | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | -1583.2% |
| Net Profit Margin | -31.7% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -818.4% | -101.7% | -44.5% | -58.4% | -49.7% | -55.7% | -68.1% | -46.1% |
| ROA | -17.7% | -17.7% | -37.7% | -50.3% | -53.6% | -37.2% | -50.6% | -43.8% | -49.1% | -61.8% | -42.6% |
| ROIC | -69.1% | -69.1% | -105.4% | -106.5% | -77.8% | -68.2% | -129.9% | -899.3% | -5304.7% | — | — |
| ROCE | -51.9% | -51.9% | -154.6% | -197.2% | -82.8% | -47.3% | -42.5% | -49.9% | -66.2% | -61.3% | -49.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 2.35 | 0.24 | 0.11 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | 0.66 | -0.27 | -0.59 | -0.94 | -0.99 | -1.04 | -1.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 5.86 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.64 | -1.64 | -4.70 | -9.76 | -17.83 | -97.17 | -217.55 | -177.75 | -1026.49 | -1281.21 | -13745.40 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 1.17 | 0.95 | 1.29 | 8.03 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
| Quick Ratio | 0.76 | 0.76 | 0.84 | 0.67 | 1.11 | 7.28 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
| Cash Ratio | 0.58 | 0.58 | 0.62 | 0.54 | 1.03 | 6.80 | 13.61 | 12.46 | 7.14 | 8.22 | 13.40 |
| Asset Turnover | — | 0.53 | 0.31 | 0.32 | 0.05 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.02 |
| Inventory Turnover | 0.34 | 0.34 | 0.15 | 0.21 | 0.09 | 0.05 | — | — | — | — | — |
| Days Sales Outstanding | — | 83.18 | 166.90 | 49.09 | 84.95 | 103.24 | 20.32 | 21.94 | 0.21 | 44.85 | 22.74 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.3% | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 3.4% | 0.3% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 1.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 1.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $61M | $58M | $56M | $56M | $55M | $51M | $47M | $41M | $34M | $27M |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ASND stock.
Ascendis Pharma A/S's current P/E ratio is 19.0x. This places it at the 50th percentile of its historical range.
Ascendis Pharma A/S's current EV/EBITDA is 64.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Based on historical data, Ascendis Pharma A/S is trading at a P/E of 19.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Ascendis Pharma A/S has 85.1% gross margin and -18.9% operating margin.
Key Metrics
Top Statement Risk
Commercial ramp execution dependence
Platform Premium Hidden Behind Trailing Multiples
Based on reported figures, ASND trades at a trailing P/E of 19.28 and forward P/E of 19.02, while EV/EBITDA of 65.55 compresses to 14.41 forward, suggesting earnings expectations are rising sharply as commercial revenue scales.
The gap between trailing EV/EBITDA of 65.55 and forward EV/EBITDA of 14.41 indicates that current EBITDA is depressed relative to what the market expects from the SKYTROFA and YORVIPATH ramp, so the trailing figure likely overstates the true valuation burden. Relative to peers such as INCY at 27.13 EV/EBITDA and ACAD at 22.02, ASND's forward multiple appears moderate, which may reflect investors pricing a platform premium rather than a single-asset discount. Investors should monitor whether forward earnings estimates hold, since a miss would quickly re-rate the stock toward its trailing multiple.
Gross Margin Strength Fails to Reach Operating Line
According to the reported income statement, ASND's gross margin held near 91.2% in 2026Q3 while operating margin reached 33.7% and net margin 20.0%, indicating operating costs still absorb a large share of gross profit.
The spread between a roughly 91% gross margin and a 33.7% operating margin shows that R&D and commercial spending consume most of the gross profit pool, which is consistent with a company still funding a multi-program pipeline. Operating margin has improved sharply from -167.3% in 2024Q3 to 33.7%, suggesting operating leverage is emerging as revenue scales faster than the expense base. The margin trajectory warrants continued monitoring, as the durability of this improvement depends on sustaining revenue growth without a proportional rise in SG&A.
ROIC Recovery Remains Fragile and Uneven
Based on reported quarterly figures, ASND's ROIC moved from -98.3% in 2024Q2 to 9.0% in 2026Q3, but the quarterly series swings between 4.2% and 9.0% in recent periods, so the compounding trend is not yet established.
The recovery in ROIC is largely a function of margin expansion, since asset turnover remains low at 0.15 and capital is tied up in a large, cash-heavy balance sheet that generates little operating return. The ROE of 5.0% in 2026Q3 against 21.9% in 2026Q2 shows how much the headline return depends on one-off items, reinforcing the need to separate recurring earnings from non-operating gains. Investors may want to see ROIC hold above its cost of capital over several consecutive quarters before concluding the business is compounding returns.
Cash Buffer Rebuilt Against Working Capital Swings
As reported in financial statements, ASND's current ratio improved to 2.89 and quick ratio to 2.29 in 2026Q3, up from 1.00 and 0.72 in 2026Q1, reflecting a cash position rebuilt to roughly $980.7M.
The jump in the current ratio from 1.00 to 2.89 across two quarters appears driven largely by cash accumulation rather than inventory build, since the quick ratio tracks the current ratio closely and inventory days are a minor component of working capital. A quick ratio above 2.0 suggests short-term obligations are covered even without inventory liquidation, which is an appropriate buffer for a company with a high fixed-cost base. Under a severe stress scenario, the main risk would be a reversal in working capital timing, which the quarterly cash flow data show can swing by tens of millions in a single period.
Days Payable Flatter Than Headline Liquidity Suggests
Based on reported figures, ASND's cash conversion cycle stood at 676 days in 2026Q3 against 993 days in 2026Q1, a figure driven heavily by a DIO near 922 days that may warrant closer scrutiny of inventory build.
The reported DIO of roughly 900 days is unusually high even for a biologics manufacturer, and combined with DPO near 307 days it produces a CCC that depends on extended supplier terms rather than fast collections. The metric most often misapplied to this business is the headline current ratio, which can flatter a company whose liquidity rests on cash from partner milestones rather than recurring product receivables. Investors should instead examine the cash conversion of operating cash flow to net income and the trend in inventory build relative to revenue before concluding the working capital profile is healthy.